Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space
Cibinqo And Rinvoq Offer Oral Alternative To Blockbuster
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.
